BioArctic's Leqembi Subcutaneous Formulation BLA Lands Acceptance in China

07:00 AM EST, 01/06/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) said Tuesday that China's National Medical Products Administration accepted a biologics license application for Leqembi's subcutaneous formulation to treat early Alzheimer's disease. If approved, patients could self-administer a 500-milligram weekly dose at home using an autoinjector, instead of the current biweekly intravenous infusion. Leqembi, developed with Japanese pharmaceutical company Eisai, is already approved in the US for subcutaneous maintenance dosing, with applications for initiation dosing under review in the US and Japan.